The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.

Download and Print: Download Printer-friendly PDF Download data

Table 19.30

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Males, 2009-2015

Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 103,504 70.7 70.4 71.1 90.3 89.3 91.1 76.7 76.3 77.2 61.4 60.7 62.1
1 Hodgkin Lymphoma 8,077 85.6 84.6 86.5 97.3 95.7 98.3 88.4 87.4 89.4 58.4 54.2 62.3
2 Non-Hodgkin lymphoma 93,329 69.8 69.4 70.3 88.7 87.5 89.7 75.4 74.9 75.9 62.0 61.3 62.7
2(a) Non-Hodgkin lymphoma, B-cell 86,191 70.3 69.8 70.7 89.5 88.3 90.6 76.3 75.8 76.9 62.5 61.8 63.3
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 4,673 68.3 66.7 69.8 88.3 86.8 89.6 42.0 38.9 45.0 14.0 9.3 19.7
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 76,969 70.6 70.1 71.0 93.8 91.7 95.4 77.7 77.2 78.3 63.1 62.3 63.8
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 20,318 80.4 79.5 81.3 89.0 43.1 98.4 87.7 86.6 88.6 74.7 73.2 76.1
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 17,359 83.9 82.9 84.9 85.8 33.2 97.9 91.0 89.9 91.9 78.4 76.8 79.9
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 59 59.5 42.0 73.3 - - - 68.8 41.3 85.3 49.0 26.6 68.1
2(a) 2.1.3. Mantle-cell lymphoma 2,900 59.8 57.3 62.3 - - - 69.4 66.1 72.5 51.5 47.7 55.2
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 1,783 80.8 77.3 83.8 - - - 88.4 84.1 91.6 76.2 71.0 80.5
2(a) 2.2.1. Lymphoplasmacytic lymphoma 753 80.5 75.0 85.0 - - - 84.9 77.8 89.9 78.0 70.0 84.1
2(a) 2.2.2. Waldenstrom macroglubulinemia 1,030 81.1 76.3 85.0 - - - 90.9 84.9 94.6 74.9 67.8 80.6
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 19,607 63.3 62.4 64.1 92.9 89.0 95.5 70.6 69.6 71.7 54.2 52.8 55.7
2(a) 2.3.1. DLBCL, NOSc 19,365 63.1 62.2 64.0 93.2 89.2 95.8 70.5 69.4 71.5 54.3 52.8 55.7
2(a) 2.3.2. Intravascular large B-cell lymphoma 27 31.5 14.0 50.7 - - - 47.3 21.4 69.5 10.6 0.6 37.9
2(a) 2.3.3. Primary effusion lymphoma 42 54.2 36.4 68.9 - - - 49.0 30.4 65.2 70.5 22.4 92.1
2(a) 2.3.4. Mediastinal large B-cell lymphoma 173 88.8 82.3 93.1 88.8 61.7 97.1 91.1 84.1 95.1 56.5 22.4 80.5
2(a) 2.4. Burkitt lymphoma/leukemia 1,587 65.3 62.6 67.9 93.1 89.7 95.4 59.8 56.2 63.1 40.0 32.1 47.7
2(a) 2.5. Marginal-zone lymphoma (MZL) 4,689 88.7 86.9 90.3 100.0 - - 92.9 91.1 94.3 84.0 80.6 86.8
2(a) 2.5.1. Splenic MZL 404 84.4 77.4 89.3 - - - 86.8 78.9 91.9 81.6 69.1 89.4
2(a) 2.5.2. Extranodal MZL, MALTc type 2,853 93.3 91.0 95.0 100.0 - - 95.4 93.2 96.9 90.5 85.8 93.7
2(a) 2.5.3. Nodal MZL 1,432 80.7 77.2 83.8 100.0 - - 88.2 84.5 91.1 72.7 66.7 77.8
2(a) 2.6. Follicular lymphoma 8,820 88.4 87.2 89.5 96.9 78.6 99.6 91.8 90.7 92.8 83.3 81.0 85.4
2(a) 2.7. Hairy-cell leukemia 1,255 94.7 91.8 96.6 - - - 96.6 95.1 97.7 87.8 79.5 92.9
2(a) 2.8. Plasma cell neoplasms 18,900 52.1 51.0 53.1 100.0 - - 61.9 60.5 63.3 43.9 42.5 45.4
2(a) 2.8.1. Plasmacytoma 1,214 69.4 65.6 72.9 100.0 - - 77.5 73.1 81.2 57.6 50.6 64.0
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 17,686 50.8 49.8 51.9 100.0 - - 60.4 59.0 61.9 43.3 41.8 44.7
2(a) 2.9. Heavy chain disease 10 59.4 18.0 85.4 100.0 - - 84.2 11.0 98.7 0.0 - -
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 4,549 67.7 65.6 69.6 92.0 73.6 97.8 75.6 73.1 78.0 61.2 58.1 64.2
2(b) Non-Hodgkin lymphoma, T-cell 6,775 65.2 63.8 66.6 85.7 82.9 88.2 67.1 65.3 68.8 52.8 49.7 55.8
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 131 63.8 54.6 71.7 91.7 81.1 96.5 43.0 29.4 55.9 0.0 - -
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 6,635 65.3 63.8 66.7 85.1 82.0 87.7 67.6 65.8 69.3 53.0 49.9 56.1
2(b) 2.1. Mycosis fungoides/Sezary syndrome 1,633 89.5 86.6 91.8 100.0 - - 90.9 88.0 93.2 85.6 78.1 90.6
2(b) 2.1.1. Mycosis fungoides 1,575 90.9 88.0 93.1 100.0 - - 91.7 88.8 93.9 88.1 80.2 93.0
2(b) 2.1.2. Sezary syndrome 58 48.9 29.1 66.0 - - - 52.0 23.3 74.5 47.8 22.5 69.3
2(b) 2.2. Peripheral T-cell lymphoma 3,446 57.0 55.0 59.0 85.7 78.6 90.6 63.3 60.8 65.7 44.2 40.5 47.9
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 1,268 40.3 37.1 43.5 69.0 47.3 83.2 48.8 44.6 52.8 27.2 22.4 32.2
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 437 36.3 30.7 41.8 100.0 - - 40.9 32.9 48.8 31.8 24.1 39.8
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 34 87.6 63.3 96.2 75.2 12.6 96.2 89.6 64.0 97.3 - - -
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 680 64.2 59.8 68.3 88.6 79.8 93.7 67.7 62.4 72.4 42.7 33.1 51.9
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 45 39.9 24.0 55.3 66.8 5.3 94.6 39.7 21.9 56.9 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 38 9.7 2.1 24.6 - - - 16.7 4.2 36.5 0.0 - -
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 671 84.7 79.8 88.4 100.0 - - 88.0 83.1 91.6 77.7 66.7 85.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 273 86.7 78.7 91.8 90.9 50.8 98.7 90.3 81.9 94.9 80.4 62.3 90.4
2(b) 2.3. Adult T-cell leukemia/lymphoma 1,146 66.2 62.9 69.2 83.9 80.1 87.1 50.4 44.9 55.6 19.4 9.7 31.5
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 284 42.3 35.3 49.2 63.7 29.7 84.5 41.5 33.3 49.5 39.7 25.5 53.4
2(b) 2.5. T-cell large granular lymphocytic leukemia 12 59.5 23.4 83.1 - - - 68.3 18.6 91.8 46.1 4.5 82.4
2(b) 2.6. Prolymphocytic leukemia, T-cell 114 17.8 9.8 27.8 - - - 23.9 12.3 37.5 8.9 1.7 23.6
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 9 31.4 4.0 66.0 - - - 27.1 1.0 69.3 - - -
2(c) Non-Hodgkin lymphoma, unknown lineage 363 50.0 44.1 55.7 81.1 66.6 89.7 51.3 43.2 58.7 35.6 25.2 46.0
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 125 53.3 43.7 62.0 82.4 67.6 90.8 50.0 32.4 65.2 20.4 8.8 35.4
2(c) 2. Prolymphocytic leukemia, unknown lineage 10 49.6 12.6 78.8 - - - - - - 38.3 4.4 74.5
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 228 47.9 40.0 55.3 50.0 0.6 91.0 50.7 41.6 59.2 41.9 27.8 55.3
2(*) 1. Total precursor lymphoma/leukemiad 4,929 67.8 66.3 69.3 88.3 86.8 89.6 42.3 39.3 45.2 14.8 10.3 20.0
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 163 80.6 72.8 86.3 - - - 83.5 74.2 89.6 73.2 57.0 84.1
4 Lymphoid neoplasm, NOSc 1,935 49.3 46.4 52.1 83.6 72.1 90.7 60.0 56.0 63.8 38.6 34.5 42.6

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.